Ekso Bionics to Present at the B. Riley & Co. Institutional Investor Conference
May 11, 2017 12:31 pm UTC| Business
RICHMOND, Calif., May 11, 2017 -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO), a robotic exoskeleton company, today announced the company plans to participate in the B. Riley Co. Institutional Investor Conference in...
Healthcare Veteran John Fletcher Joins MRI Interventions’ Board of Directors
May 11, 2017 12:30 pm UTC| Business
IRVINE, Calif., May 11, 2017 -- MRI Interventions, Inc. (OTCQB:MRIC) is pleased to announce that John Fletcher has been appointed to MRI Interventions’ Board of Directors. Mr. Fletcher, founder and managing partner of...
Pacific Ethanol to Participate in the 12th Annual BMO Capital Markets Farm to Market Conference
May 11, 2017 12:30 pm UTC| Business
SACRAMENTO, Calif., May 11, 2017 -- Pacific Ethanol, Inc. (NASDAQ:PEIX), a leading producer and marketer of low-carbon renewable fuels in the United States, announced CFO Bryon McGregor will present at the 12th Annual...
May 11, 2017 12:30 pm UTC| Business
On track to file for clinical trial authorization (CTA) for lead program in beta-thalassemia in 2017Expanded partnerships enhancing both ex vivo and in vivo delivery of CRISPR/Cas9 technologyExpanded foundational and...
May 11, 2017 12:30 pm UTC| Business
NEW YORK, May 11, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of Florida on behalf of investors who purchased TherapeuticsMD,...
Drone USA, Inc. Apppoints New Board Member With Extensive Drone Manufacturing Expertise
May 11, 2017 12:30 pm UTC| Business
NEW YORK, May 11, 2017 -- Drone USA, Inc. (OTC Markets:DRUS) (“Drone USA” or the “Company”), a developer and manufacturer of low altitude Unmanned Aerial Vehicles (“UAVs”) and related technologies, today announced that...
ORPHAZYME COMPLETES ENROLMENT OF PATIENTS FOR PHASE 3 CLINICAL TRIAL IN NIEMANN-PICK TYPE C DISEASE
May 11, 2017 12:29 pm UTC| Business
Copenhagen, 11 May 2017 Orphazyme ApS, a Danish biotech company developing novel therapies for the treatment of protein misfolding diseases, today announced the completion of enrolment for its lead program within...